<unk>  (development codes AZD0914 and ETX0914) is an experimental antibiotic that is being studied for the treatment of infection with Neisseria gonorrhoeae (gonorrhea). It has a novel mechanism of action which involves inhibition of bacterial type II topoisomerases. It is being developed by Entasis Therapeutics and is (as of 2020) in Phase III clinical trials.
Zoliflodacin
Proglumetacin
Indometacin farnesil
Hydramacin-1
Mesterolone
Butaperazine
Ibotenic acid
Hydrastinine